Study of Dasatinib in Patients With Chronic Phase Chronic Myeloid Leukemia and a Suboptimal Response to Imatinib
Status:
Terminated
Trial end date:
2010-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the efficacy of dasatinib with that of high-dose
(800-mg) imatinib in participants with chronic phase chronic myeloid leukemia who achieved
only a suboptimal response after at least 3 months of monotherapy with 400-mg imatinib. The
safety of these treatments will also be evaluated.